SUVENPHAR2023-10-012023-12-31 SUVENPHAR2023-10-012023-12-31 SUVENPHAR2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2023-10-012023-12-31in-bse-fin:OneOperatingExpenses03Member SUVENPHAR2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member SUVENPHAR2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member SUVENPHAR2023-10-012023-12-31in-bse-fin:FourOperatingExpenses03Member SUVENPHAR2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543064 SUVENPHAR NOTLISTED Suven Pharmaceuticals Limited Equity 2023-04-01 2024-03-31 2024-02-05 2024-01-29 INR Lakhs Third quarter 15:30:00 17:05:00 2024-02-05 2024-02-05 Not applicable Single segment Contract Development and Manufacturing 2023-10-01 2023-12-31 Unaudited Consolidated 2198196000.00 143446000.00 2341642000.00 635259000.00 0.00 89134000.00 328325000.00 12690000.00 127518000.00 494033000.00 1686959000.00 654683000.00 0.00 654683000.00 146503000.00 40645000.00 187148000.00 0.00 467535000.00 0.00 0.00 0.00 0.00 467535000.00 -8451000.00 459084000.00 0.00 0.00 254565000.00 1 1.84 1.84 0.00 0.00 1.84 1.84 Notes: 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 5th February2024 Results for the for the quarter ended 31st December , 2023 has been reviewed by our statutory auditors. 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the wholly owned subsidiarIes Suven Pharma, Inc.,USA & Casper Pharma Pvt Ltd. 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5) As per share purchase agreement dated 26th December'2022 entered into by and between Berhyanda Limited (Buyer), Jasti Property and Equity Holdings private limited (in their capacity as sole trustee of Jasti Family Trust) (Seller) and Mr.Venkatesearlu Jasti (Seller representative) pursuant to SEBI SAST Regulations, 2011 as amended, M/s Berhyanda Limited, a Cyprus based company and an investment arm of Adven Internationsl Corporation , USA has acquired controlling stake to the tune of 11,75,37,043 equity shares aggregating to 50.10% in the company on 29th September, 2023 from the seller . 6) The corresponding previous period figures have been regrouped/reclassified where ever necessary. Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 7984234000.00 448514000.00 8432748000.00 1944537000.00 0.00 368605000.00 901533000.00 29183000.00 371849000.00 1468844000.00 5084551000.00 3348197000.00 0.00 3348197000.00 802536000.00 76586000.00 879122000.00 0.00 2469075000.00 0.00 0.00 0.00 0.00 2469075000.00 -8360000.00 2460715000.00 0.00 0.00 254565000.00 1 9.70 9.70 0.00 0.00 9.70 9.70 Manufacturing Expenses 327026000.00 Other Expenses 144185000.00 R & D expenses 22822000.00 Manufacturing Expenses 942565000.00 Other Expenses 437838000.00 R & D expenses 88441000.00 -11292000.00 -11171000.00 -2841000.00 -2811000.00 0.00 0.00